Most patients received guideline-directed medical therapy for HF, including beta-blockers (85%), angiotensin–converting enzyme (ACE) inhibitors (36%), angiotensin II receptor blockers (ARBs) (44%), angiotensin receptor–neprilysin inhibitors (ARNIs) (9%), calcium channel blockers (33%), and SGLT2 inhibitors (14%). This evidence concerns the gene SLC5A2 and hydrops fetalis.